中外制药公司的抗人源IL-31受体A的单克隆抗体nemolizumab治疗中重度特应性皮炎的Ⅱ期临床试验资料在新英格兰医学杂志上发表。Ⅱ期临床XCIMA试验入选264名中重度特应性皮炎患者,随机按1∶1∶1∶1分到nemolizumab(0.1、0.5、2.0 mg/kg每4周1次)和安慰剂组。主终点是治疗12周后,与安慰剂组比,瘙痒数值评定量表得分改善情况。nemolizumab 0.1、0.5和2.0 mg/kg每4周1次组分别为-43.7%、-59.8%和-63.1%, Chinese and foreign pharmaceutical companies anti-human IL-31 receptor A monoclonal antibody nemolizumab treatment of moderate-to-severe atopic dermatitis phase Ⅱ clinical trial data published in the New England Journal of Medicine. A total of 264 patients with moderate-to-severe atopic dermatitis were enrolled in the phase II clinical XCIMA trial. Nemolizumab (0.1, 0.5, 2.0 mg / kg every 4 weeks) and placebo were randomized at 1: 1: 1: 1. The primary endpoint was improvement in pruritus numerical rating scale scores after 12 weeks of treatment compared with placebo. nemolizumab at 0.1, 0.5 and 2.0 mg / kg every 4 weeks were -43.7%, -59.8% and -63.1% respectively,